Processing

Please wait...

Settings

Settings

Goto Application

1. WO2014078468 - BIOMARKERS FOR PREDICTING CLINICAL RESPONSE OF CANCER PATIENTS TO TREATMENT WITH IMMUNOTHERAPEUTIC AGENT

Publication Number WO/2014/078468
Publication Date 22.05.2014
International Application No. PCT/US2013/069975
International Filing Date 14.11.2013
IPC
C12Q 1/68 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
CPC
C07K 16/2818
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
2818against CD28 or CD152
C07K 2317/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
C12Q 2600/106
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
C12Q 2600/118
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
118Prognosis of disease development
C12Q 2600/158
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
158Expression markers
Applicants
  • BRISTOL-MYERS SQUIBB COMPANY [US]/[US]
Inventors
  • ARTOMOV, Maksym
  • CHASALOW, Scott D.
  • FOWLER, Kevin Daniel
  • JI, Rui-Ru
  • SHAHABI, Vafa
  • TOWFIC, Fadi George
  • ZESKIND, Benjamin James
Agents
  • HAI, Bing
Priority Data
61/726,95315.11.2012US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) BIOMARKERS FOR PREDICTING CLINICAL RESPONSE OF CANCER PATIENTS TO TREATMENT WITH IMMUNOTHERAPEUTIC AGENT
(FR) BIOMARQUEURS DESTINÉS À PRÉDIRE UNE RÉPONSE CLINIQUE DE PATIENTS CANCÉREUX SUITE À UN TRAITEMENT AVEC UN AGENT IMMUNOTHÉRAPEUTIQUE
Abstract
(EN)
Provided herein are prognostic and diagnostic methods for predicting likelihood of clinical response of a subject having cancer to treatment with an immunotherapeutic agent. Also provided herein are methods for treating a subject having cancer with an immunotherapeutic agent after determining likelihood of clinical response of the subject to such treatment.
(FR)
La présente invention concerne des méthodes de pronostic et de diagnostic permettant de prédire la probabilité d'une réponse clinique d'un sujet atteint d'un cancer à un traitement avec un agent immunothérapeutique. L'invention concerne également des méthodes permettant de traiter un sujet atteint d'un cancer avec un agent immunothérapeutique après la détermination de la probabilité d'une réponse clinique du sujet à un tel traitement.
Also published as
Latest bibliographic data on file with the International Bureau